绝经激素治疗与血管舒缩症状女性的心血管疾病:女性健康倡议随机临床试验的二次分析
该研究为两项女性健康倡议随机临床试验的二次分析,纳入40个美国临床中心27 347名50–79岁绝经后女性,比较结合马雌激素0.625 mg/日单用或联合醋酸甲羟孕酮2.5 mg/日与安慰剂的动脉粥样硬化性心血管病风险。中位随访7.2年(单用试验)和5.6年(联合试验)。50–59岁有中重度血管舒缩症状者,单用结合马雌激素HR 0.85(95%CI 0.53–1.35),联合方案HR 0.84(95%CI 0.44–1.57),均无显著影响。70岁及以上有血管舒缩症状者风险增加:单用HR 1.95(95%CI 1.06–3.59),每万人年超额事件217例;联合方案HR 3.22(95%CI 1.36–7.63),每万人年超额事件382例。
要点
- 50–59岁有中重度血管舒缩症状者,单用结合马雌激素动脉粥样硬化性心血管病HR 0.85(95%CI 0.53–1.35),联合醋酸甲羟孕酮HR 0.84(95%CI 0.44–1.57),均无显著影响。
- 70岁及以上有血管舒缩症状者,单用结合马雌激素动脉粥样硬化性心血管病HR 1.95(95%CI 1.06–3.59),每万人年超额事件217例。
- 70岁及以上有血管舒缩症状者,联合醋酸甲羟孕酮动脉粥样硬化性心血管病HR 3.22(95%CI 1.36–7.63),每万人年超额事件382例。
- 60–69岁有血管舒缩症状者,单用结合马雌激素HR 1.31(95%CI 0.90–1.90),联合方案HR 0.84(95%CI 0.51–1.39),无明确伤害信号。
- 单用结合马雌激素使各年龄组血管舒缩症状减少41%(总体RR 0.59;95%CI 0.53–0.66)。
适用人群与场景
- 两项随机临床试验的二次分析,纳入50–79岁绝经后女性,来自40个美国临床中心,数据收集自1993年11月至2012年9月。
- 共27 347名女性,平均(SD)年龄63.4(7.2)岁;10 739名(39.3%)有子宫切除史,16 608名(60.7%)子宫完整。
- 单用结合马雌激素试验中,基线有中重度血管舒缩症状者:50–59岁905名(27.6%),60–69岁705名(14.7%),70–79岁220名(8.7%)。
- 联合醋酸甲羟孕酮试验中,基线有中重度血管舒缩症状者:50–59岁1225名(22.4%),60–69岁649名(8.7%),70–79岁172名(4.8%)。
- 入组时有中重度血管舒缩症状的女性中,3382名(96.7%)回忆症状始于绝经前后。
处置流程与药物剂量
- 结合马雌激素(CEE)0.625 mg/日,单用或联合醋酸甲羟孕酮(MPA)2.5 mg/日,与安慰剂对照。
- 作者结论支持指南推荐:50–59岁有血管舒缩症状的女性可用激素治疗;60–69岁启动激素治疗需谨慎;70岁及以上避免使用激素治疗。
研究设计与关键结果
- 研究类型:两项随机临床试验的二次分析;样本量27 347名;来自40个美国临床中心;人群为50–79岁绝经后女性。
- 干预:结合马雌激素0.625 mg/日单用或联合醋酸甲羟孕酮2.5 mg/日 vs 安慰剂;主要终点为动脉粥样硬化性心血管病(非致死性心肌梗死、心绞痛住院、冠状动脉血运重建、缺血性卒中、外周动脉疾病、颈动脉疾病或心血管死亡的复合终点)。
- 单用结合马雌激素试验中位(IQR)随访7.2(6.4–8.1)年;联合醋酸甲羟孕酮试验中位随访5.6(4.8–6.5)年。
- 50–59岁有中重度血管舒缩症状者,单用结合马雌激素动脉粥样硬化性心血管病HR 0.85(95%CI 0.53–1.35),联合醋酸甲羟孕酮HR 0.84(95%CI 0.44–1.57),均无显著影响。
- 70岁及以上有血管舒缩症状者,单用结合马雌激素HR 1.95(95%CI 1.06–3.59),每万人年超额事件217例,交互作用趋势P=0.03;联合醋酸甲羟孕酮HR 3.22(95%CI 1.36–7.63),每万人年超额事件382例,交互作用趋势P=0.02。
- 60–69岁有血管舒缩症状者,单用结合马雌激素HR 1.31(95%CI 0.90–1.90),联合醋酸甲羟孕酮HR 0.84(95%CI 0.51–1.39),无明确伤害信号。
- 单用结合马雌激素使各年龄组血管舒缩症状减少41%(总体RR 0.59;95%CI 0.53–0.66);联合醋酸甲羟孕酮试验中血管舒缩症状减少随年龄衰减(50–59岁:RR 0.41;95%CI 0.35–0.48;60–69岁:RR 0.72;95%CI 0.61–0.85;70–79岁:RR 1.20;95%CI 0.91–1.59;交互作用趋势P<0.001)。
证据类型、等级与局限
- 证据类型:两项随机临床试验的二次分析。
- 试验注册号:ClinicalTrials.gov NCT00000611。
- 局限:原文未报告局限性。
对床旁实践的改变
- 50–59岁有中重度血管舒缩症状的绝经后女性,单用结合马雌激素0.625 mg/日或联合醋酸甲羟孕酮2.5 mg/日不显著增加动脉粥样硬化性心血管病风险,作者结论支持指南在该人群中用激素治疗血管舒缩症状的推荐。
- 60–69岁有血管舒缩症状的女性启动激素治疗需谨慎,作者引用指南建议此年龄段谨慎启动。
- 70岁及以上有血管舒缩症状的女性,单用结合马雌激素或联合醋酸甲羟孕酮均增加动脉粥样硬化性心血管病风险(HR 1.95和3.22),作者结论支持指南避免在该人群使用激素治疗。
指南或共识出处
- 女性健康倡议随机临床试验(ClinicalTrials.gov NCT00000611)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Identification of appropriate patients for treatment of vasomotor symptoms (VMS) with menopausal hormone therapy (HT) is challenging.
OBJECTIVE: To assess risk of cardiovascular disease (CVD) due to HT in women with VMS.
DESIGN, SETTING, AND PARTICIPANTS: In this secondary analysis of 2 randomized clinical trials of HT, postmenopausal women aged 50 to 79 years from 40 US clinical centers were included. Data were collected from November 1993 to September 2012, and data were analyzed from December 2024 to May 2025.
INTERVENTIONS: Conjugated equine estrogens (CEE), 0.625 mg per day, or CEE with medroxyprogesterone acetate (MPA), 2.5 mg per day, vs placebo.
MAIN OUTCOMES AND MEASURES: Atherosclerotic CVD (ASCVD; defined as composite of nonfatal myocardial infarction, hospitalization for angina, coronary revascularization, ischemic stroke, peripheral arterial disease, carotid artery disease, or CVD death).
RESULTS: Of 27 347 included postmenopausal women, the mean (SD) age was 63.4 (7.2) years; a total of 10 739 (39.3%) had a hysterectomy, and 16 608 (60.7%) had an intact uterus. The median (IQR) follow-up was 7.2 (6.4-8.1) years and 5.6 (4.8-6.5) years for those in the CEE alone trial and the CEE plus MPA trial, respectively. In the CEE alone trial, moderate or severe VMS were present at baseline in 905 (27.6%), 705 (14.7%), and 220 (8.7%) women aged 50 to 59 years, 60 to 69 years, and 70 to 79 years, respectively; in the CEE plus MPA trial, moderate or severe VMS was present in 1225 (22.4%), 649 (8.7%), and 172 (4.8%), respectively. Among women with moderate or severe VMS at enrollment, 3382 (96.7%) recalled having symptoms near menopause onset. CEE alone reduced VMS by 41% across all age groups (overall relative risk [RR], 0.59; 95% CI, 0.53-0.66). However, in the CEE plus MPA trial, VMS reduction was attenuated with age (age 50-59 years: RR, 0.41; 95% CI, 0.35-0.48; age 60-69 years: RR, 0.72; 95% CI, 0.61-0.85; age 70-79 years: RR, 1.20; 95% CI, 0.91-1.59; interaction P for trend < .001). Both CEE alone and CEE plus MPA appeared to have neutral effects on ASCVD in women with moderate or severe VMS aged 50 to 59 years (CEE alone: hazard ratio [HR], 0.85; 95% CI, 0.53-1.35; CEE plus MPA: HR, 0.84; 95% CI, 0.44-1.57). While the estimated risk was higher for CEE alone in women with VMS aged 60 to 69 years, there was no clear signal of harm (CEE alone: HR, 1.31; 95% CI, 0.90-1.90; CEE plus MPA: HR, 0.84; 95% CI, 0.51-1.39). However, women with VMS 70 years and older had increased risks of ASCVD (CEE alone: HR, 1.95; 95% CI, 1.06-3.59; 217 excess events per 10 000 person-years; interaction P for trend = .03; CEE plus MPA: HR, 3.22; 95% CI, 1.36-7.63; 382 excess events per 10 000 person-years; interaction P for trend = .02).
CONCLUSIONS AND RELEVANCE: In this secondary analysis of 2 randomized clinical trials, among younger postmenopausal women aged 50 to 59 years, both CEE alone and CEE plus MPA reduced VMS without significantly affecting ASCVD risk. In women with VMS 70 years and older, risks for ASCVD were increased in both trials. The findings support guideline recommendations for treatment of VMS with HT in women aged 50 to 59 years, caution if initiating HT in women aged 60 to 69 years, and avoidance of HT in women 70 years and older.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00000611.
参考来源
- Rossouw JE, Aragaki AK, Manson JE, et al. Menopausal Hormone Therapy and Cardiovascular Diseases in Women With Vasomotor Symptoms: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. JAMA Intern Med. 2025. PMID: 40952729. doi:10.1001/jamainternmed.2025.4510
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。